Filana Therapeutics, Inc. (FLNA) stock
FLNANasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.64+0.08 (+14.52%)
Close on Nov 20, 2026Market cap $30.98MP/E –Yield –
Filana Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Filana Therapeutics's free cash flow for the twelve months ending Dec 31, 2025 was -$32.83M. For fiscal 2025 it was -$32.83M. The highest annual figure on record is -$2.53M in fiscal 2019.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$32.83M | – |
| FY2024 | Dec 31, 2024 | -$117.03M | – |
| FY2023 | Dec 31, 2023 | -$82.44M | – |
| FY2022 | Dec 31, 2022 | -$80.23M | – |
| FY2021 | Dec 31, 2021 | -$52.41M | – |
| FY2019 | Dec 31, 2019 | -$2.53M | – |
| FY2016 | Dec 31, 2016 | -$12.31M | – |
| FY2015 | Dec 31, 2015 | -$9.25M | – |
| FY2014 | Dec 31, 2014 | -$9.63M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | -$10.25M | – |
| Q3 FY2025 | Sep 30, 2025 | -$6.30M | – |
| Q2 FY2025 | Jun 30, 2025 | -$4.95M | – |
| Q1 FY2025 | Mar 31, 2025 | -$11.34M | – |
| Q4 FY2024 | Dec 31, 2024 | -$61.32M | – |
| Q3 FY2024 | Sep 30, 2024 | -$18.31M | – |
| Q2 FY2024 | Jun 30, 2024 | -$18.27M | – |
| Q1 FY2024 | Mar 31, 2024 | -$19.13M | – |
| Q4 FY2023 | Dec 31, 2023 | -$22.36M | – |
| Q3 FY2023 | Sep 30, 2023 | -$26.55M | – |
| Q2 FY2023 | Jun 30, 2023 | -$19.92M | – |
| Q1 FY2023 | Mar 31, 2023 | -$13.61M | – |
| Q4 FY2022 | Dec 31, 2022 | -$20.99M | – |
| Q3 FY2022 | Sep 30, 2022 | -$22.71M | – |
| Q2 FY2022 | Jun 30, 2022 | -$12.58M | – |
| Q1 FY2022 | Mar 31, 2022 | -$23.96M | – |
| Q4 FY2021 | Dec 31, 2021 | -$8.09M | – |
| Q3 FY2021 | Sep 30, 2021 | -$36.81M | – |
| Q4 FY2019 | Dec 31, 2019 | -$589.00K | – |
| Q3 FY2019 | Sep 30, 2019 | -$730.00K | – |
| Q2 FY2019 | Jun 30, 2019 | -$591.00K | – |
| Q1 FY2019 | Mar 31, 2019 | -$622.00K | – |
| Q4 FY2016 | Dec 31, 2016 | -$3.03M | – |
See a number that looks wrong?